{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T21:43:45Z","timestamp":1792532625315,"version":"4.5.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,15]],"date-time":"2024-12-15T00:00:00Z","timestamp":1734220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020275","name":"TauRx Pharmaceuticals","doi-asserted-by":"publisher","award":["PAR1562"],"award-info":[{"award-number":["PAR1562"]}],"id":[{"id":"10.13039\/100020275","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020275","name":"TauRx Pharmaceuticals","doi-asserted-by":"publisher","award":["PAR 1763"],"award-info":[{"award-number":["PAR 1763"]}],"id":[{"id":"10.13039\/100020275","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain Research Bulletin"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.brainresbull.2024.111172","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T13:01:22Z","timestamp":1734354082000},"page":"111172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Rivastigmine interferes with the pharmacological activity of hydromethylthionine on presynaptic proteins in the line 66 model of frontotemporal dementia"],"prefix":"10.1016","volume":"220","author":[{"given":"Karima","family":"Schwab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianne","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Annschuetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eline","family":"Dreesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy","family":"Magbagbeolu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Melis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Theuring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles R.","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude M.","family":"Wischik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2374-6281","authenticated-orcid":false,"given":"Gernot","family":"Riedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.brainresbull.2024.111172_bib1","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/alz.12068","volume":"16","author":"2020 Alzheimer\u2019s disease facts and figures","year":"2020","journal-title":"Alzheimer's Dement"},{"key":"10.1016\/j.brainresbull.2024.111172_bib2","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1056\/NEJMp2110468","article-title":"Revisiting FDA approval of aducanumab","volume":"385","author":"Alexander","year":"2021","journal-title":"New Eng. J. Med."},{"issue":"21","key":"10.1016\/j.brainresbull.2024.111172_bib3","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1016\/j.jmb.2018.08.010","article-title":"Cysteine-independent inhibition of Alzheimer\u2019s disease-like paired helical filament assembly by leuco-methylthioninium (LMT)","volume":"430","author":"Al-Hilaly","year":"2018","journal-title":"J. Mol. Biol."},{"issue":"1","key":"10.1016\/j.brainresbull.2024.111172_bib4","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3233\/JAD-231034","article-title":"A meta-analysis on presynaptic changes in Alzheimer\u2019s disease","volume":"97","author":"Anschuetz","year":"2024","journal-title":"J. Alheimer's. Dis."},{"issue":"1","key":"10.1016\/j.brainresbull.2024.111172_bib5","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1124\/jpet.114.219352","article-title":"Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer\u2019s disease","volume":"352","author":"Baddeley","year":"2015","journal-title":"J. Pharm. Exp. Ther."},{"issue":"3","key":"10.1016\/j.brainresbull.2024.111172_bib6","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0014-2999(99)00643-3","article-title":"Effect of rivastigmine on scopolamine-induced memory impairment in rats","volume":"383","author":"Bejar","year":"1999","journal-title":"Eur. J. Pharm."},{"issue":"7","key":"10.1016\/j.brainresbull.2024.111172_bib7","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0330-23.2024","article-title":"The lack of synapsin alters presynaptic plasticity at hippocampal mossy fibers in male mice","volume":"11","author":"Bruentgens","year":"2024","journal-title":"eNeuro"},{"issue":"14","key":"10.1016\/j.brainresbull.2024.111172_bib8","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1016\/j.neuron.2023.04.020","article-title":"Synaptic oligomeric tau in Alzheimer\u2019s disease \u2014 a potential culprit in the spread of tau pathology through the brain","volume":"111","author":"Colom-Cadena","year":"2023","journal-title":"Neuron"},{"issue":"5","key":"10.1016\/j.brainresbull.2024.111172_bib9","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nrn2631","article-title":"Microtubule assembly, organization and dynamics in axons and dendrites","volume":"10","author":"Conde","year":"2009","journal-title":"Nat. Rev. Neurosci."},{"issue":"1","key":"10.1016\/j.brainresbull.2024.111172_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-021-00772-0","article-title":"In vivo tau pathology is associated with synaptic loss and altered synaptic function","volume":"13","author":"Coomans","year":"2021","journal-title":"Alzheimer's Res Ther."},{"issue":"June","key":"10.1016\/j.brainresbull.2024.111172_bib11","article-title":"Rescue of synaptosomal glutamate release defects in tau transgenic mice by the tau aggregation inhibitor Hydromethylthionine","volume":"121","author":"Cranston","year":"2024","journal-title":"Cell Signal"},{"issue":"1","key":"10.1016\/j.brainresbull.2024.111172_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/braincomms\/fcaa033","article-title":"Cholinergic and inflammatory phenotypes in transgenic tau mouse models of Alzheimer\u2019s disease and frontotemporal lobar degeneration","volume":"2","author":"Cranston","year":"2020","journal-title":"Brain Commun."},{"issue":"6","key":"10.1016\/j.brainresbull.2024.111172_bib13","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jalz.2015.12.005","article-title":"Meta-analysis of synaptic pathology in Alzheimer\u2019s disease reveals selective molecular vesicular machinery vulnerability","volume":"12","author":"De Wilde","year":"2016","journal-title":"Alzheimer's Dement"},{"issue":"7","key":"10.1016\/j.brainresbull.2024.111172_bib14","article-title":"The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research","volume":"18","author":"du Sert","year":"2020","journal-title":"PLoS Biol."},{"issue":"3","key":"10.1016\/j.brainresbull.2024.111172_bib15","first-page":"169","article-title":"First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer\u2019s disease","volume":"2","author":"Ferrero","year":"2016","journal-title":"Alzheimer's Dement Transl. Res Clin. Inter."},{"issue":"10062","key":"10.1016\/j.brainresbull.2024.111172_bib16","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1016\/S0140-6736(16)31275-2","article-title":"Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer\u2019s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial","volume":"388","author":"Gauthier","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.brainresbull.2024.111172_bib17","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/0896-6273(89)90210-9","article-title":"Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer\u2019s disease","volume":"3","author":"Goedert","year":"1989","journal-title":"Neuron"},{"issue":"17","key":"10.1016\/j.brainresbull.2024.111172_bib18","doi-asserted-by":"crossref","first-page":"10862","DOI":"10.1074\/jbc.M114.616029","article-title":"Cellular models of aggregation-dependent template-directed proteolysis to characterize Tau aggregation inhibitors for treatment of Alzheimer disease","volume":"290","author":"Harrington","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.brainresbull.2024.111172_bib19","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1750-3639.2012.00598.x","article-title":"Extensive p-Tau pathology and SDS-stable p-Tau oligomers in Alzheimer\u2019s cortical synapses","volume":"22","author":"Henkins","year":"2012","journal-title":"Brain Pathol."},{"issue":"3","key":"10.1016\/j.brainresbull.2024.111172_bib20","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.3233\/JAD-171087","article-title":"Progress and challenges in frontotemporal dementia research: A 20-Year Review","volume":"62","author":"Hodges","year":"2018","journal-title":"J. Alzheimer's Dis."},{"key":"10.1016\/j.brainresbull.2024.111172_bib21","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.73542","article-title":"Microtubule assembly by soluble tau impairs vesicle endocytosis and excitatory neurotransmission via dynamin sequestration in Alzheimer\u2019s disease mice synapse model","volume":"11","author":"Hori","year":"2022","journal-title":"Elife"},{"issue":"4","key":"10.1016\/j.brainresbull.2024.111172_bib22","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/alz.12213","article-title":"Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019","volume":"17","author":"Knopman","year":"2021","journal-title":"Alzheimer's Dement"},{"issue":"2","key":"10.1016\/j.brainresbull.2024.111172_bib23","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/jnc.15553","article-title":"Hydromethylthionine enhancement of central cholinergic signalling is blocked by rivastigmine and memantine","volume":"160","author":"Kondak","year":"2022","journal-title":"J. Neurochem"},{"key":"10.1016\/j.brainresbull.2024.111172_bib24","article-title":"Emerging perspectives of synaptic biomarkers in ALS and FTD","volume":"16","author":"Krishnamurthy","year":"2023","journal-title":"Front Mol. Neurosci."},{"issue":"5","key":"10.1016\/j.brainresbull.2024.111172_bib25","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.neuron.2011.04.001","article-title":"Synaptophysin regulates the kinetics of synaptic vesicle endocytosis in central neurons","volume":"70","author":"Kwon","year":"2011","journal-title":"Neuron"},{"issue":"7","key":"10.1016\/j.brainresbull.2024.111172_bib26","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.tcb.2017.02.002","article-title":"\u03b1-Synuclein \u2013 regulator of exocytosis, endocytosis, or both?","volume":"27","author":"Lautenschl\u00e4ger","year":"2017","journal-title":"Trends Cell Biol."},{"issue":"52","key":"10.1016\/j.brainresbull.2024.111172_bib27","doi-asserted-by":"crossref","first-page":"18508","DOI":"10.1074\/jbc.RA120.014890","article-title":"Differential compartmental processing and phosphorylation of pathogenic human tau and native mouse tau in the line 66 model of frontotemporal dementia","volume":"295","author":"Lemke","year":"2020","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.brainresbull.2024.111172_bib28","article-title":"Cholinesterase inhibitors for rarer dementias associated with neurological conditions","author":"Li","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.brainresbull.2024.111172_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-43130-4","article-title":"Tau forms synaptic nano-biomolecular condensates controlling the dynamic clustering of recycling synaptic vesicles","volume":"14","author":"Longfield","year":"2023","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.brainresbull.2024.111172_bib30","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.neuron.2018.01.022","article-title":"Synaptogyrin-3 mediates presynaptic dysfunction induced by tau","volume":"97","author":"McInnes","year":"2018","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/j.brainresbull.2024.111172_bib31","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/FBP.0000000000000133","article-title":"Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models","volume":"26","author":"Melis","year":"2015","journal-title":"Behav. Pharm."},{"issue":"11","key":"10.1016\/j.brainresbull.2024.111172_bib32","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1007\/s00018-014-1804-z","article-title":"Different pathways of molecular pathophysiology underlie cognitive and motor tauopathy phenotypes in transgenic models for Alzheimer\u2019s disease and frontotemporal lobar degeneration","volume":"72","author":"Melis","year":"2015","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.brainresbull.2024.111172_bib33","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.69236","article-title":"The mesoscale organization of syntaxin 1A and SNAP25 is determined by SNARE-SNARE interactions","volume":"10","author":"Mertins","year":"2021","journal-title":"Elife"},{"issue":"3","key":"10.1016\/j.brainresbull.2024.111172_bib34","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.3390\/ijms15034671","article-title":"Tau protein modifications and interactions: Their role in function and dysfunction","volume":"15","author":"Mietelska-Porowska","year":"2014","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.brainresbull.2024.111172_bib35","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000203829","article-title":"Fosgonimeton provides congruent improvements on neurodegeneration biomarkers, significantly correlating with composite clinical score of cognition and function in Alzheimer\u2019s disease","author":"Moebius","year":"2023","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.brainresbull.2024.111172_bib36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J. Basic Clin. Pharm."},{"issue":"1","key":"10.1016\/j.brainresbull.2024.111172_bib37","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/life11010028","article-title":"Tau oligomers neurotoxicity","volume":"11","author":"Niewiadomska","year":"2021","journal-title":"Life"},{"issue":"8","key":"10.1016\/j.brainresbull.2024.111172_bib38","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s40266-019-00685-6","article-title":"Use of Cholinesterase inhibitors in non-Alzheimer\u2019s dementias","volume":"36","author":"Noufi","year":"2019","journal-title":"Drugs Aging"},{"key":"10.1016\/j.brainresbull.2024.111172_bib39","series-title":"Paxinos and Franklin's the Mouse Brain in Stereotaxic Coordinates","author":"Paxinos","year":"2019"},{"issue":"4","key":"10.1016\/j.brainresbull.2024.111172_bib40","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S0149-2918(98)80127-6","article-title":"Clinical pharmacology of rivastigmine: A new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer\u2019s disease","volume":"20","author":"Polinsky","year":"1998","journal-title":"Clin. Ther."},{"key":"10.1016\/j.brainresbull.2024.111172_bib41","unstructured":"Prince M. World Alzheimer Report. Published online 2015. \u3008https:\/\/www.alz.co.uk\/research\/WorldAlzheimerReport2015.pdf\u3009."},{"key":"10.1016\/j.brainresbull.2024.111172_bib42","unstructured":"R Core Team, 2021. R: A Language and Environment for Statistical Computing. https:\/\/www.R-project.org\/."},{"issue":"3","key":"10.1016\/j.brainresbull.2024.111172_bib43","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2174\/1567205017666200224120926","article-title":"Mechanisms of anticholinesterase interference with tau aggregation inhibitor activity in a tau-transgenic mouse model","volume":"17","author":"Riedel","year":"2020","journal-title":"Curr. Alzheimer Res"},{"issue":"149","key":"10.1016\/j.brainresbull.2024.111172_bib44","first-page":"1","article-title":"Synaptic tau: A pathological or physiological phenomenon?","volume":"9","author":"Robbins","year":"2021","journal-title":"Acta Neuropathol. Commun."},{"issue":"4","key":"10.1016\/j.brainresbull.2024.111172_bib45","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3390\/biomedicines10040867","article-title":"HMTM-mediated enhancement of brain bioenergetics in a mouse tauopathy model is blocked by chronic administration of rivastigmine","volume":"10","author":"Santos","year":"2022","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.brainresbull.2024.111172_bib46","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3233\/JAD-190772","article-title":"Concentration-dependent activity of hydromethylthionine on cognitive decline and brain atrophy in mild to moderate Alzheimer\u2019s disease","volume":"72","author":"Schelter","year":"2019","journal-title":"J. Alzheimer's Dis"},{"key":"10.1016\/j.brainresbull.2024.111172_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2022.110386","article-title":"Glutamatergic transmission and receptor expression in the synucleinopathy h-\u03b1-synL62 mouse model: Effects of hydromethylthionine","volume":"97","author":"Schwab","year":"2022","journal-title":"Cell Signal"},{"key":"10.1016\/j.brainresbull.2024.111172_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainresbull.2024.110955","article-title":"Hydromethylthionine rescues synaptic SNARE proteins in a mouse model of tauopathies: interference by cholinesterase inhibitors","volume":"212","author":"Schwab","year":"2024","journal-title":"Brain Res. Bull."},{"issue":"8","key":"10.1016\/j.brainresbull.2024.111172_bib49","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.3390\/cells10082162","article-title":"Proteomic analysis of hydromethylthionine in the line 66 model of frontotemporal dementia demonstrates actions on tau-dependent and tau-independent networks","volume":"10","author":"Schwab","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.brainresbull.2024.111172_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.796129","article-title":"Imaging synaptic density: the next holy grail of neuroscience?","volume":"16","author":"Serrano","year":"2022","journal-title":"Front Neurosci."},{"issue":"7618","key":"10.1016\/j.brainresbull.2024.111172_bib51","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.brainresbull.2024.111172_bib52","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3233\/JAD-191173","article-title":"Concentration-dependent activity of hydromethylthionine on clinical decline and brain atrophy in a randomized controlled trial in behavioral variant frontotemporal dementia","volume":"75","author":"Shiells","year":"2020","journal-title":"J. Alzheimer's Dis."},{"issue":"6","key":"10.1016\/j.brainresbull.2024.111172_bib53","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.brainresbull.2024.111172_bib54","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/jnc.12991","article-title":"Pre-synaptic C-terminal truncated tau is released from cortical synapses in Alzheimer\u2019s disease","volume":"133","author":"Sokolow","year":"2015","journal-title":"J. Neurochem"},{"issue":"11","key":"10.1016\/j.brainresbull.2024.111172_bib55","doi-asserted-by":"crossref","first-page":"936","DOI":"10.14348\/molcells.2015.0233","article-title":"Synapsin isoforms and synaptic vesicle trafficking","volume":"38","author":"Song","year":"2015","journal-title":"Mol. Cells"},{"issue":"4","key":"10.1016\/j.brainresbull.2024.111172_bib56","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.neuron.2014.05.004","article-title":"The intersection of amyloid beta and tau at synapses in Alzheimer\u2019s disease","volume":"82","author":"Spires-Jones","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.brainresbull.2024.111172_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2020.592607","article-title":"Synaptic loss in Alzheimer\u2019s disease: mechanistic insights provided by two-photon in vivo imaging of transgenic mouse Models","volume":"14","author":"Subramanian","year":"2020","journal-title":"Front Cell Neurosci."},{"issue":"23","key":"10.1016\/j.brainresbull.2024.111172_bib58","doi-asserted-by":"crossref","first-page":"11113","DOI":"10.1073\/pnas.1903049116","article-title":"Functional cooperation of \u03b1-synuclein and VAMP2 in synaptic vesicle recycling","volume":"166","author":"Sun","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.brainresbull.2024.111172_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-020-00663-w","article-title":"Aducanumab, gantenerumab, BAN2401, and ALZ-801 - The first wave of amyloid-targeting drugs for Alzheimer\u2019s disease with potential for near term approval","volume":"12","author":"Tolar","year":"2020","journal-title":"Alzheimer's Res. Ther."},{"issue":"4","key":"10.1016\/j.brainresbull.2024.111172_bib60","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.cell.2021.12.041","article-title":"Tau interactome maps synaptic and mitochondrial processes associated with neurodegeneration","volume":"185","author":"Tracy","year":"2022","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.brainresbull.2024.111172_bib61","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00213-004-2132-z","article-title":"Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model","volume":"180","author":"Van Dam","year":"2005","journal-title":"Psychopharmacol. (Berl. )"},{"key":"10.1016\/j.brainresbull.2024.111172_bib62","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.12688\/f1000research.14506.1","article-title":"Current understanding of Alzheimer\u2019s disease diagnosis and treatment","volume":"7","author":"Weller","year":"2018","journal-title":"F1000Research"},{"issue":"1","key":"10.1016\/j.brainresbull.2024.111172_bib63","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3233\/JAD-170560","article-title":"Potential of low dose leuco-methylthioninium bis(hydromethanesulphonate) (LMTM) monotherapy for treatment of mild Alzheimer\u2019s disease: cohort analysis as modified primary outcome in a phase III Clinical Trial","volume":"61","author":"Wilcock","year":"2018","journal-title":"J. Alzheimer's Dis."},{"issue":"2","key":"10.1016\/j.brainresbull.2024.111172_bib64","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3233\/JAD-142874","article-title":"Tau aggregation inhibitor therapy: An exploratory phase 2 study in mild or moderate Alzheimer\u2019s disease","volume":"44","author":"Wischik","year":"2015","journal-title":"J. Alzheimer's Dis."},{"key":"10.1016\/j.brainresbull.2024.111172_bib65","doi-asserted-by":"crossref","DOI":"10.6064\/2012\/796024","article-title":"The role of tau in neurodegenerative diseases and its potential as a therapeutic target","author":"Wolfe","year":"2012","journal-title":"Scientifica (Cairo)"},{"issue":"1","key":"10.1016\/j.brainresbull.2024.111172_bib66","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3233\/JAD-230975","article-title":"Association of basal forebrain volume with amyloid, tau, and cognition in Alzheimer\u2019s disease","volume":"99","author":"Yoo","year":"2024","journal-title":"J. Alzheimer's Dis."},{"issue":"7","key":"10.1016\/j.brainresbull.2024.111172_bib67","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3390\/cells13070642","article-title":"Neuroprotection of cholinergic neurons with a tau aggregation inhibitor and rivastigmine in an Alzheimer\u2019s-like tauopathy mouse model","volume":"13","author":"Zadrozny","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.brainresbull.2024.111172_bib68","doi-asserted-by":"crossref","first-page":"15295","DOI":"10.1038\/ncomms15295","article-title":"Tau association with synaptic vesicles causes presynaptic dysfunction","volume":"8","author":"Zhou","year":"2017","journal-title":"Nat. Commun."}],"container-title":["Brain Research Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036192302400306X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036192302400306X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:25:30Z","timestamp":1778505930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S036192302400306X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":68,"alternative-id":["S036192302400306X"],"URL":"https:\/\/doi.org\/10.1016\/j.brainresbull.2024.111172","relation":{},"ISSN":["0361-9230"],"issn-type":[{"value":"0361-9230","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rivastigmine interferes with the pharmacological activity of hydromethylthionine on presynaptic proteins in the line 66 model of frontotemporal dementia","name":"articletitle","label":"Article Title"},{"value":"Brain Research Bulletin","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brainresbull.2024.111172","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"111172"}}